RAF1 and central nervous system cancer: Due to the only recent inclusion of RAF/MEK inhibitors in clinical trials for gliomas and central nervous system tumors, the knowledge toward resistance mechanisms to target therapy is limited and is mainly obtained by data coming from melanoma and colorectal cancer (69, 87–91).